Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

22
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
22
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

24
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to...
24
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

377
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
377
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

271
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
Gastrointestinal Motility Disorders01:20

Gastrointestinal Motility Disorders

1.6K
Gastrointestinal or GI motility disorders are characterized by irregular gastrointestinal tract movements, disrupting food transit from the mouth to the anus. They are caused by damage or dysfunction in gut muscles or nerves. These disorders can cause symptoms such as severe constipation, diarrhea, abdominal pain, and swallowing difficulties. Disorders can affect any segment of the GI tract and range widely in severity, from common conditions like GERD to life-threatening conditions like...
1.6K
Factors Influencing Drug Absorption: Disease States and Pharmacology01:25

Factors Influencing Drug Absorption: Disease States and Pharmacology

1.9K
Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Performance measures for endoscopic ultrasound: a European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative - Update 2025.

Endoscopy·2025
Same author

EUS Guided FNA Cell Block Cytology and Intraoperative Squash Cytology in the Diagnostic Approach of Unfamiliar Malignant Neoplastic Disorders.

Acta medica (Hradec Kralove)·2025
Same author

Results of the COLDWATER randomized controlled trial: enhanced performance of underwater cold snare polypectomy for colorectal polyps 5-10 mm, independent of endoscopist experience.

Annals of gastroenterology·2024
Same author

Bariatric Nutritional Intervention in Obese Patients with Compensated Liver Cirrhosis: A Four-Year Prospective Study.

Digestive diseases and sciences·2024
Same author

Curriculum for diagnostic endoscopic ultrasound training in Europe: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement.

Endoscopy·2023
Same author

The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review.

European journal of clinical pharmacology·2023

Related Experiment Video

Updated: Apr 21, 2026

Author Spotlight: Reliable and Reproducible In Vitro Assessment of Drug Impact on Rat Intestinal Tubes
06:01

Author Spotlight: Reliable and Reproducible In Vitro Assessment of Drug Impact on Rat Intestinal Tubes

Published on: July 26, 2024

1.0K

Gastrointestinal dysfunction in liver cirrhosis.

Evangelos Kalaitzakis1

  • 1Evangelos Kalaitzakis, Department of Gastroenterology, Skåne University Hospital, University of Lund, 22185 Lund, Sweden.

World Journal of Gastroenterology
|October 31, 2014
PubMed
Summary

Gut dysfunction is common in liver cirrhosis, affecting nutrition and quality of life. Delayed gut transit and intestinal barrier issues may drive cirrhosis complications.

Keywords:
Gastric accommodationGastrointestinal symptomsGut motilityIntestinal permeabilityLiver cirrhosisMalnutrition

More Related Videos

The Murine Choline-Deficient, Ethionine-Supplemented CDE Diet Model of Chronic Liver Injury
07:27

The Murine Choline-Deficient, Ethionine-Supplemented CDE Diet Model of Chronic Liver Injury

Published on: October 21, 2017

11.2K
Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
08:56

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

56.4K

Related Experiment Videos

Last Updated: Apr 21, 2026

Author Spotlight: Reliable and Reproducible In Vitro Assessment of Drug Impact on Rat Intestinal Tubes
06:01

Author Spotlight: Reliable and Reproducible In Vitro Assessment of Drug Impact on Rat Intestinal Tubes

Published on: July 26, 2024

1.0K
The Murine Choline-Deficient, Ethionine-Supplemented CDE Diet Model of Chronic Liver Injury
07:27

The Murine Choline-Deficient, Ethionine-Supplemented CDE Diet Model of Chronic Liver Injury

Published on: October 21, 2017

11.2K
Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
08:56

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

56.4K

Area of Science:

  • Gastroenterology and Hepatology
  • Microbiome Research

Background:

  • Patients with liver cirrhosis often experience gut dysfunction.
  • This dysfunction impacts nutritional status and quality of life.
  • Pathophysiology involves liver disease severity, psychological distress, and gut issues like delayed transit.

Purpose of the Study:

  • To explore the multifaceted gut dysfunction in liver cirrhosis.
  • To understand the link between gut issues and cirrhosis complications.
  • To investigate the impact on nutritional status and quality of life.

Main Methods:

  • Review of existing literature on gastrointestinal symptoms in cirrhosis.
  • Analysis of factors influencing gastric sensitivity and gut transit times.
  • Examination of studies on gastric emptying, small bowel transit, and related hormonal disturbances.
  • Investigation of small bowel bacterial overgrowth and intestinal barrier function.

Main Results:

  • Gastrointestinal symptoms are prevalent and linked to liver disease severity and psychological distress.
  • Gastric accommodation data in non-ascitic cirrhotics is inconsistent; tense ascites negatively impacts it.
  • Gastric emptying and small bowel transit are generally prolonged, associated with altered glucose, insulin, and ghrelin levels, and insulin resistance.
  • Delayed transit correlates with small bowel bacterial overgrowth.
  • Intestinal barrier dysfunction and bacterial translocation are observed, particularly in portal hypertension.

Conclusions:

  • Gut dysfunction is a significant feature of liver cirrhosis, contributing to complications.
  • Delayed transit, bacterial overgrowth, and impaired intestinal barrier function are key issues.
  • These gut-related problems potentially play a role in the pathogenesis of cirrhosis complications.